Metastatic HER2-Positive Breast Cancer


Metastatic HER2-Positive Breast Cancer overview



Metastatic HER2-Positive Breast Cancer is one type of breast cancer in which test for breast cancer cells shows a positive sign for a protein receptor known as human epidermal growth factor receptor 2. The usual function of this protein is to regulate a healthy breast cell how it grows, divides, and repairs itself.

However, when there is a mutation in the gene that controls the HER2 protein, also called as erythroblastosis oncogene B (ERBB2) gene, the body produces too many HER2 receptors, which leads to uncontrollable breast cell growth and division. Some of the most common symptoms of Metastatic HER2-Positive Breast Cancer are breast swelling, change in the shape of breast, skin irritation or dimpling, pain in the breast, redness or thickness of the breast skin.

A HER2-positive breast cancer diagnosis is confirmed by tests, such as the IHC test, the FISH test, the SPOT-Light HER2 CISH, and the Inform HER2 Dual ISH tests. These tests utilize antibodies or DNA to stain the cancer cells.

Metastatic HER2-Positive Breast Cancer Epidemiology

Breast cancer total incident population in the 7MM was found to be 626,867 in 2017, which is anticipated to rise during the study period [2017–2028]. A higher Breast cancer incidence was observed in the United States. Among the EU-5 countries, Germany ranked the first, followed by Italy, and France, while Spain witnessed the least number of breast cancer cases in 2017.

Metastatic HER2-Positive Breast Cancer Market Scenario

The market comprises a variety of options for the Metastatic HER-2 Positive Breast Cancer treatment. It is mainly categorized into pharmacological and non-pharmacological therapies. A medical oncologist generally prescribes systemic therapies. Common ways to give systemic therapies include an intravenous (IV) tube or can be given orally.
The systemic therapies used for metastatic breast cancer include Targeted Therapy and Hormonal therapy (Endocrine therapy). 

On the other hand, hormonal therapy market also includes Aromatase Inhibitors that reduce the production of estrogen by inhibiting the aromatase enzyme activity in peripheral tissues and within the tumour microenvironment. The market landscape of aromatase inhibitors mainly depends on three agents, Exemestane (Pharmacia & Upjohn Company), Anastrozole (AstraZeneca), and Letrozole (Novartis Pharmaceuticals).

Key players that are producing drugs for Metastatic HER-2 Positive Breast Cancer such as MacroGenics, Puma Biotechnology, Seattle Genetics, Jiangsu HengRui Medicine, Prestige Biopharma Pte Ltd, EirGenix, Inc., and others are involved in developing therapies.


Comments

  1. Blog27999February 28, 2020 at 4:58 AM

    If you're trying to lose kilograms then you absolutely have to start following this brand new custom keto plan.

    To design this keto diet, licensed nutritionists, fitness couches, and chefs united to provide keto meal plans that are powerful, painless, price-efficient, and delightful.

    Since their first launch in January 2019, thousands of people have already completely transformed their body and health with the benefits a professional keto plan can offer.

    Speaking of benefits: in this link, you'll discover 8 scientifically-confirmed ones offered by the keto plan.

    ReplyDelete

Post a Comment

Popular posts from this blog

Tenosynovial Giant Cell Tumors (TSGCTs) Market Research Report 2030 | Tenosynovial Giant Cell Tumors (TSGCTs) Market

Image
Tenosynovial Giant Cell Tumors   are a type of neoplasm that affects synovial-lined tendon sheaths, synovial joints, and surrounding soft tissue. Locally aggressive benign tissue lesions are defined by synovial lining inflammation in joints and tendons. Overexpression of the colony-stimulating factor 1 receptor is thought to cause these tumors to form. Giant cell tumors of the tendon sheath (GCTTS), pigmented villonodular tumors (PVNTS), extra-articular pigmented villonodular tumors of the tendon sheath, and localized or focal nodular synovitis are all terms used to describe TSGCTs. Tenosynovial Giant Cell Tumors Causes Translocation is an alteration to a chromosome that causes Tenosynovial Giant Cell Tumors. A chromosome segment breaks off and moves around. The cause of these translocations is unknown. The genetic code for making proteins is stored on chromosomes. A protein termed colony-stimulating factor 1 is produced in excess due to the translocation (CSF1). This protein attracts
Read more

Functional Dyspepsia Market Research Report 2030 | Functional Dyspepsia Market

Image
  Functional dyspepsia   is a term for recurring signs and symptoms of indigestion that have no apparent cause. Functional dyspepsia is also called non-ulcer stomach pain or non-ulcer dyspepsia. It's not clear what causes functional dyspepsia. Doctors consider it a functional disorder, which means that routine testing may not show any abnormalities. Hence, it is diagnosed based on symptoms. Functional Dyspepsia Signs and Symptoms  Functional dyspepsia is common and can be long-lasting — although signs and symptoms are mostly intermittent. These signs and symptoms resemble those of an ulcer, discomfort in your upper abdomen, often accompanied by bloating, belching, and nausea, An early feeling of fullness (satiety) when eating, Pain in the stomach that may sometimes occur unrelated to meals, or maybe relieved with meals. Functional Dyspepsia Epidemiology According to an article by Madisch et al. (2018), Functional Dyspepsia is one of the common functional disorders, with a prevalenc
Read more

Fibrodysplasia Ossificans Progressiva Market Research Report 2030 | Fibrodysplasia Ossificans Progressiva Market

Image
  Fibrodysplasia ossificans progressiva   is a disorder in which the skeleton, muscles, and connective tissues, such as tendons and ligaments, are replaced by bone (ossified). This position was to lead to the formation of the bones of the skeleton (extra-skeletal or heterotopic bone) that constrains movement. Fibrodysplasia ossificans progressiva Causes Fibrodysplasia ossificans progressiva is called a mutation in the ACVR1 gene. This gene is involved in bone growth and development. Mutations, and the possibility of a disorderly development. The gene can be inherited from a parent, but in most cases, the, is a new mutation, a person with a less-than-a family history of the disease. As a parent, they have a 50% chance of passing it on to their children. Fibrodysplasia ossificans progressiva Sign and Symptoms The  Fibrodysplasia ossificans progressiva  symptoms begin in the first decade of life with episodes of painful inflammatory soft tissue swellings. Gradually, there occurs restricti
Read more